{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:22:55Z","timestamp":1789708975754,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["324105"],"award-info":[{"award-number":["324105"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antibiotic prophylaxis is recommended during ANCA-associated vasculitis (AAV) induction. We aimed to describe the frequency, persistence, and factors associated with trimethoprim-sulfamethoxazole (TMP-SMX) use in an adult population sample with granulomatosis with polyangiitis (GPA) treated with rituximab (RTX).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified adults with GPA treated with RTX within the Merative\u2122 Marketscan\u00ae Research Databases (2011\u20132020). TMP-SMX prophylaxis was defined as a <jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mo>\u2265<\/mml:mo>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 28-day prescription dispensed within a month of starting RTX. We estimated TMP-SMX persistence, allowing prescription refill gaps of 30 days. Multivariable logistic regression and Cox proportional hazards regression assessed the factors associated with baseline TMP-SMX use and persistence, respectively. Covariates included age, sex, calendar year, insurance type, immunosuppressant use, hospitalization, and co-morbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 1877 RTX-treated GPA patients, the mean age was 50.9, and 54% were female. A minority (<jats:italic>n<\/jats:italic>\u2009=\u2009426, 23%) received TMP-SMX with a median persistence of 141 (IQR 83\u2013248) days. In multivariable analyses, prophylaxis was associated with prednisone use in the month prior to RTX (<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mo>\u2265<\/mml:mo>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 20\u00a0mg\/day vs none, OR 3.96; 95% CI 3.0\u20135.2; 1\u201319\u00a0mg\/day vs none, OR 2.63; 95% CI 1.8\u20133.8), and\u00a0methotrexate use (OR 1.48, 95% CI 1.04\u20132.1), intensive care (OR 1.95; 95% CI 1.4\u20132.7), and non-intensive care hospitalization (OR 1.56; 95% CI 1.2\u20132.1) in the 6\u00a0months prior to RTX. Female sex (OR 0.63; 95% CI 0.5\u20130.8) was negatively associated with TMP-SMX use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TMP-SMX was dispensed to a minority of RTX-treated GPA patients, more often to those on glucocorticoids and with recent hospitalization. Further research is needed to determine the optimal use and duration of TMP-SMX prophylaxis\u00a0following RTX in AAV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03114-7","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T04:01:42Z","timestamp":1690603302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-616X","authenticated-orcid":false,"given":"Arielle","family":"Mendel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Behlouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano Soares","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9velyne","family":"Vinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"1","key":"3114_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3114_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3899\/jrheum.200721","volume":"48","author":"A Mendel","year":"2021","unstructured":"Mendel A, Ennis D, Go E, Bakowsky V, Baldwin C, Benseler SM, Cabral DA, Carette S, Clements-Baker M, Clifford AH, et al. CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update. J Rheumatol. 2021;48(4):555\u201366.","journal-title":"J Rheumatol"},{"issue":"8","key":"3114_CR3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366\u201383.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3114_CR4","doi-asserted-by":"publisher","first-page":"rky025","DOI":"10.1093\/rap\/rky025","volume":"2","author":"FA Pearce","year":"2018","unstructured":"Pearce FA, McGrath C, Sandhu R, Packham J, Watts RA, Rhodes B, Al-Jayyousi R, Harper L, Obrenovic K, Lanyon P. Outcomes and compliance with standards of care in anti-neutrophil cytoplasmic antibody-associated vasculitis-insights from a large multiregion audit. Rheumatol Adv Pract. 2018;2(2):rky025.","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"3114_CR5","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s10067-018-4067-5","volume":"37","author":"J Yoo","year":"2018","unstructured":"Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clin Rheumatol. 2018;37(8):2133\u201341.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3114_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1080\/14397595.2016.1226468","volume":"27","author":"K Watanabe-Imai","year":"2017","unstructured":"Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H, Amano K, Ito S, Homma S, Kumagai S, et al. Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2017;27(4):646\u201351.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"3114_CR7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","volume":"54","author":"F Alberici","year":"2015","unstructured":"Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, Smith KG, Jayne DR. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54(7):1153\u201360.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3114_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12882-018-0933-2","volume":"19","author":"L Yang","year":"2018","unstructured":"Yang L, Xie H, Liu Z, Chen Y, Wang J, Zhang H, Ge Y, Hu W. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018;19(1):138.","journal-title":"BMC Nephrol"},{"issue":"3","key":"3114_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigole G, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3114_CR10","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/art.40577","volume":"70","author":"S Panupattanapong","year":"2018","unstructured":"Panupattanapong S, Stwalley DL, White AJ, Olsen MA, French AR, Hartman ME. Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large national claims database. Arthritis Rheumatol. 2018;70(12):2067\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3114_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12882-018-1102-3","volume":"19","author":"D Titeca-Beauport","year":"2018","unstructured":"Titeca-Beauport D, Francois A, Lobbedez T, Guerrot D, Launay D, Vrigneaud L, Daroux M, Lebas C, Bienvenu B, Hachulla E, et al. Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. BMC Nephrol. 2018;19(1):317.","journal-title":"BMC Nephrol"},{"issue":"2","key":"3114_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.55563\/clinexprheumatol\/ammhi6","volume":"39 Suppl 129","author":"JA Singh","year":"2021","unstructured":"Singh JA. Infection versus cardiovascular disease as leading causes of hospitalisations and associated mortality in vasculitis in the U.S.: a national study. Clin Exp Rheumatol. 2021;39 Suppl 129(2):56\u201361.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"3114_CR13","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"3114_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","volume":"46","author":"C Lapraik","year":"2007","unstructured":"Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D\u2019Cruz D, Guillevin L, Harper L, Jayne D, Luqmani R, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3114_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","volume":"42","author":"P Charles","year":"2013","unstructured":"Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla E, Hamidou M, Harle JR, Karras A, Lega JC, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med. 2013;42(10):1317\u201330.","journal-title":"Presse Med"},{"issue":"3","key":"3114_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3114_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335(1):16\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"3114_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, Smith RM, Jayne DRW. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3114_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.55563\/clinexprheumatol\/p34lkr","volume":"39 Suppl 129","author":"D Waki","year":"2021","unstructured":"Waki D, Nishimura K, Yoshida T, Tanaka N, Mizukawa K, Fukushima M, Iri O, Anegawa M, Murabe H, Yokota T. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Clin Exp Rheumatol. 2021;39 Suppl 129(2):142\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"3114_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023;82(5):681\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3114_CR21","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","volume":"59","author":"J Tieu","year":"2020","unstructured":"Tieu J, Smith R, Basu N, Brogan P, D\u2019Cruz D, Dhaun N, Flossmann O, Harper L, Jones RB, Lanyon PC, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020;59(4):e24\u201332.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3114_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40744-018-0099-1","volume":"5","author":"AM Kong","year":"2018","unstructured":"Kong AM, Kim G, Michalska M, Best JH. Costs of disease relapses among individuals with granulomatosis with polyangiitis or microscopic polyangiitis in the United States. Rheumatol Ther. 2018;5(1):159\u201370.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"3114_CR23","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3899\/jrheum.150479","volume":"42","author":"K Raimundo","year":"2015","unstructured":"Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42(12):2383\u201391.","journal-title":"J Rheumatol"},{"issue":"12","key":"3114_CR24","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/pds.4116","volume":"25","author":"AG Sreih","year":"2016","unstructured":"Sreih AG, Annapureddy N, Springer J, Casey G, Byram K, Cruz A, Estephan M, Frangiosa V, George MD, Liu M, et al. Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. Pharmacoepidemiol Drug Saf. 2016;25(12):1368\u201374.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"3114_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/acr2.11274","volume":"3","author":"V Benard","year":"2021","unstructured":"Benard V, Farhat C, Zarandi-Nowroozi M, Durand M, Charles P, Puechal X, Guillevin L, Pagnoux C, Makhzoum JP. Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody-associated vasculitis: systematic review and meta-analysis. ACR Open Rheumatol. 2021;3(7):484\u201394.","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"3114_CR26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","volume":"48","author":"G Schmajuk","year":"2019","unstructured":"Schmajuk G, Jafri K, Evans M, Shiboski S, Gianfrancesco M, Izadi Z, Patterson SL, Aggarwal I, Sarkar U, Dudley RA, et al. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum. 2019;48(6):1087\u201392.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"3114_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park JW, Curtis JR, Jun KI, Kim TM, Heo DS, Ha J, Suh KS, Lee KW, Lee H, Yang J, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest. 2022;161(5):1201\u201310.","journal-title":"Chest"},{"issue":"16","key":"3114_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1503\/cmaj.131430","volume":"186","author":"DM Shafran","year":"2014","unstructured":"Shafran DM, Bunce PE, Gold WL. Reducing the risk of infection in a 74-year-old man who is to receive prednisone. CMAJ. 2014;186(16):1239\u201340.","journal-title":"CMAJ"},{"issue":"7","key":"3114_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3899\/jrheum.201330","volume":"48","author":"ZS Wallace","year":"2021","unstructured":"Wallace ZS, Yun H, Curtis JR, Chen L, Stone JH, Choi HK. ANCA-associated vasculitis management in the United States: data from the Rheumatology Informatics System for Effectiveness (RISE) Registry. J Rheumatol. 2021;48(7):1060\u20134.","journal-title":"J Rheumatol"},{"key":"3114_CR30","doi-asserted-by":"publisher","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O, Kronbichler A, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223764.","DOI":"10.1136\/ard-2022-223764"},{"issue":"3","key":"3114_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"3114_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3114_CR33","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt W, Puechal X, Fujimoto S, Hawley CM, Khalidi NA, Flossmann O, Wald A, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"3114_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"3114_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3114_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00277-021-04438-7","volume":"100","author":"S Raso","year":"2021","unstructured":"Raso S, Napolitano M, Arrigo G, Reale F, Lucchesi A, Silimbani P, Maggio A, Calvaruso G, Consoli U, Mannina D, et al. Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. Ann Hematol. 2021;100(3):653\u20139.","journal-title":"Ann Hematol"},{"issue":"8","key":"3114_CR37","doi-asserted-by":"publisher","first-page":"778.e771","DOI":"10.1016\/j.amjmed.2009.01.034","volume":"122","author":"E Macy","year":"2009","unstructured":"Macy E, Poon KYT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122(8):778.e771-777.","journal-title":"Am J Med"},{"issue":"6","key":"3114_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1086\/591126","volume":"47","author":"N Shehab","year":"2008","unstructured":"Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735\u201343.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3114_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1758-5996-6-117","volume":"6","author":"S Butalia","year":"2014","unstructured":"Butalia S, Lewin AM, Simpson SH, Dasgupta K, Khan N, Pilote L, Johnson JA, Ghali WA, Rabi DM. Sex-based disparities in cardioprotective medication use in adults with diabetes. Diabetol Metab Syndr. 2014;6(1):117.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"3114_CR40","doi-asserted-by":"publisher","first-page":"e055952","DOI":"10.1136\/bmjopen-2021-055952","volume":"12","author":"RA Benson","year":"2022","unstructured":"Benson RA, Okoth K, Keerthy D, Gokhale K, Adderley NJ, Nirantharakumar K, Lasserson DS. Analysis of the relationship between sex and prescriptions for guideline-recommended therapy in peripheral arterial disease, in relation to 1-year all-cause mortality: a primary care cohort study. BMJ Open. 2022;12(3):e055952.","journal-title":"BMJ Open"},{"issue":"9","key":"3114_CR41","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/acr.24332","volume":"73","author":"PA Merkel","year":"2021","unstructured":"Merkel PA, Niles JL, Mertz LE, Lehane PB, Pordeli P, Erblang F. Long-term safety of rituximab in granulomatosis with polyangiitis and in microscopic polyangiitis. Arthritis Care Res (Hoboken). 2021;73(9):1372\u20138.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03114-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T04:03:07Z","timestamp":1690603387000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03114-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03114-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the McGill University Faculty of Medicine Institutional Review Board (22-01-037). The requirement for individual participant consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JRC reports grants or contracts from Abbvie, Amgen, Aqtual, Bendcare, BMS, CorEvitas, FASTER, GSK, IlluminationHealth, Janssen, Labcorp, Lilly, Myriad, Novartis, Pfizer, Scipher, Setpoint, Tnacity Blue Ocean, UCB, outside of the submitted work, and consulting fees from Abbvie, Amgen, Aqtual, Bendcare, BMS, CorEvitas, FASTER, GSK, IlluminationHealth, Janssen, Labcorp, Lilly, Myriad, Novartis, Pfizer, Scipher, Setpoint, Tnacity Blue Ocean, UCB, outside the submitted work. All other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}